Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 3Glioblastoma 3Lung Neoplasms 2Astrocytoma 2Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma 1Ependymoma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 38Radiotherapy 21Radiosurgery 21Irinotecan 11Cyclophosphamide 11Radiation 10Magnetic Resonance Spectroscopy 10Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9Filgrastim 8Carboplatin 8pembrolizumab 7Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5cediranib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Valacyclovir × Clear all
NCT06914479 2026-05-27

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

University of Michigan Rogel Cancer Center

Phase 1 Recruiting
11 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡